Restricted accessResearch articleFirst published online 2014-03
Partial Correction of the CNS Lysosomal Storage Defect in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis by Neonatal CNS Administration of an Adeno-Associated Virus Serotype rh.10 Vector Expressing the Human CLN3 Gene
Juvenile neuronal ceroid lipofuscinosis (JNCL or CLN3 disease) is an autosomal recessive lysosomal storage disease resulting from mutations in the CLN3 gene that encodes a lysosomal membrane protein. The disease primarily affects the brain with widespread intralysosomal accumulation of autofluorescent material and fibrillary gliosis, as well as the loss of specific neuronal populations. As an experimental treatment for the CNS manifestations of JNCL, we have developed a serotype rh.10 adeno-associated virus vector expressing the human CLN3 cDNA (AAVrh.10hCLN3). We hypothesized that administration of AAVrh.10hCLN3 to the Cln3Δex7/8 knock-in mouse model of JNCL would reverse the lysosomal storage defect, as well as have a therapeutic effect on gliosis and neuron loss. Newborn Cln3Δex7/8 mice were administered 3×1010 genome copies of AAVrh.10hCLN3 to the brain, with control groups including untreated Cln3Δex7/8 mice and wild-type littermate mice. After 18 months, CLN3 transgene expression was detected in various locations throughout the brain, particularly in the hippocampus and deep anterior cortical regions. Changes in the CNS neuronal lysosomal accumulation of storage material were assessed by immunodetection of subunit C of ATP synthase, luxol fast blue staining, and periodic acid-Schiff staining. For all parameters, Cln3Δex7/8 mice exhibited abnormal lysosomal accumulation, but AAVrh.10hCLN3 administration resulted in significant reductions in storage material burden. There was also a significant decrease in gliosis in AAVrh.10hCLN3-treated Cln3Δex7/8 mice, and a trend toward improved neuron counts, compared with their untreated counterparts. These data demonstrate that AAVrh.10 delivery of a wild-type cDNA to the CNS is not harmful and instead provides a partial correction of the neurological lysosomal storage defect of a disease caused by a lysosomal membrane protein, indicating that this may be an effective therapeutic strategy for JNCL and other diseases in this category.
Get full access to this article
View all access options for this article.
References
1.
AnzaiY., HayashiM., FuekiN., et al. (2006). Protracted juvenile neuronal ceroid lipofuscinosis—an autopsy report and immunohistochemical analysis. Brain Dev., 28, 462–465.
2.
AuttiT., RaininkoR., SantavuoriP., et al. (1997). MRI of neuronal ceroid lipofuscinosis. II. Postmortem MRI and histopathological study of the brain in 16 cases of neuronal ceroid lipofuscinosis of juvenile or late infantile type. Neuroradiology, 39, 371–377.
3.
BibleE., GuptaP., HofmannS.L., et al. (2004). Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis., 16, 346–359.
4.
BowersW.J., BreakefieldX.O., and Sena-EstevesM. (2011). Genetic therapy for the nervous system. Hum. Mol. Genet., 20, R28–R41.
5.
BronsonR.T., DonahueL.R., JohnsonK.R., et al. (1998). Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am. J. Med. Genet., 77, 289–297.
6.
CaoY., EspinolaJ.A., FossaleE., et al. (2006). Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem., 281, 20483–20493.
7.
CearleyC.N., and WolfeJ.H. (2006). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther., 13, 528–537.
8.
ChangM., CooperJ.D., SleatD.E., et al. (2008). Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther., 16, 649–656.
9.
ClinicalTrials.gov (2011). AAVRh.10 administered to children with late infantile neuronal ceroid lipofuscinosis with uncommon genotypes or moderate/severe impairment. Available at http://clinicaltrials.gov/ct2/show/NCT01414985 (accessed September2013).
10.
CotmanS.L., VrbanacV., LebelL.A., et al. (2002). Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet., 11, 2709–2721.
11.
CrystalR.G., SondhiD., HackettN.R., et al. (2004). Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther., 15, 1131–1154.
12.
CuervoA.M. (2004). Autophagy: in sickness and in health. Trends Cell Biol., 14, 70–77.
13.
DalyT.M., OkuyamaT., VoglerC., et al. (1999a). Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther., 10, 85–94.
14.
DalyT.M., VoglerC., LevyB., et al. (1999b). Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA, 96, 2296–2300.
15.
FossaleE., WolfP., EspinolaJ.A., et al. (2004). Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci., 5, 57.
16.
GettyA.L., and PearceD.A. (2011). Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell Mol. Life Sci., 68, 453–474.
HaltiaM. (2006). The neuronal ceroid-lipofuscinoses: from past to present. Biochim. Biophys. Acta, 1762, 850–856.
19.
HerrmannP., Druckrey-FiskaaenC., KouznetsovaE., et al. (2008). Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis. J. Neurosci. Res., 86, 1857–1870.
20.
HofmanI., KohlschutterA., SantavuoriP., et al. (1999). CLN3 juvenile NCL. In The Neuronal Ceroid Lipofuscinoses (Batten Disease). GoebelH.H., ed. (IOS Press, Birmingham, AL), pp. 55–76.
21.
JansonC., McPheeS., BilaniukL., et al. (2002). Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther., 13, 1391–1412.
22.
JarvelaI., LehtovirtaM., TikkanenR., et al. (1999). Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum. Mol. Genet., 8, 1091–1098.
23.
JollyR.D., MartinusR.D., and PalmerD.N. (1992). Sheep and other animals with ceroid-lipofuscinoses: their relevance to Batten disease. Am. J. Med. Genet., 42, 609–614.
24.
KuronenM., LehesjokiA.E., JalankoA., et al. (2012). Selective spatiotemporal patterns of glial activation and neuron loss in the sensory thalamocortical pathways of neuronal ceroid lipofuscinosis 8 mice. Neurobiol. Dis., 47, 444–457.
25.
LeoneP., SheraD., McPheeS.W., et al. (2012). Long-term follow-up after gene therapy for canavan disease. Sci. Transl. Med., 4, 165ra163.
26.
LernerT.J. (2001). Positional cloning of the JNCL gene, CLN3. Adv. Genet., 45, 107–121.
27.
LoW.D., QuG., SferraT.J., et al. (1999). Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther., 10, 201–213.
28.
MaoQ., FosterB.J., XiaH., et al. (2003). Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett., 541, 40–46.
29.
MarkM., TeletinM., AntalC., et al. (2007). Histopathology in mouse metabolic investigations. Curr. Protoc. Mol. Biol. Chapter, 29, Unit 29B.4.
30.
McManusJ.F. (1948). Histological and histochemical uses of periodic acid. Stain Technol., 23, 99–108.
31.
MichalewskiM.P., KaczmarskiW., GolabekA.A., et al. (1999). Posttranslational modification of CLN3 protein and its possible functional implication. Mol. Genet. Metab., 66, 272–276.
32.
MingozziF., and HighK.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet., 12, 341–355.
33.
MitchisonH.M., BernardD.J., GreeneN.D., et al. (1999). Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis., 6, 321–334.
34.
MunroeP.B., MitchisonH.M., O'RaweA.M., et al. (1997). Spectrum of mutations in the Batten disease gene, CLN3. Am. J. Hum. Genet., 61, 310–316.
35.
NeufeldE.F., and FratantoniJ.C. (1970). Inborn errors of mucopolysaccharide metabolism. Science, 169, 141–146.
36.
NortonW.T., AquinoD.A., HozumiI., et al. (1992). Quantitative aspects of reactive gliosis: a review. Neurochem. Res., 17, 877–885.
37.
PalmerD.N., FearnleyI.M., WalkerJ.E., et al. (1992). Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am. J. Med. Genet., 42, 561–567.
38.
PaxinosG., and FranklinK.B.J. (2001). The Mouse Brain in Stereotaxic Coordinates (Academic Press, San Diego, CA).
39.
PetersenA., LarsenK.E., BehrG.G., et al. (2001). Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet., 10, 1243–1254.
40.
PolitoV.A., AbbondanteS., PolishchukR.S., et al. (2010). Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum. Mol. Genet., 19, 4871–4885.
41.
PontikisC.C., CellaC.V., PariharN., et al. (2004). Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res., 1023, 231–242.
42.
PontikisC.C., CotmanS.L., MacDonaldM.E., et al. (2005). Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol. Dis., 20, 823–836.
43.
PuntelM., KroegerK.M., SandersonN.S., et al. (2010). Gene transfer into rat brain using adenoviral vectors. Curr. Protoc. Neurosci. Chapter, 4, Unit 4.24.
44.
RafiM.A., RaoH.Z., LuziP., et al. (2012). Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol. Ther., 20, 2031–2042.
45.
RakhejaD., NarayanS.B., and BennettM.J. (2008). The function of CLN3P, the Batten disease protein. Mol. Genet. Metab., 93, 269–274.
46.
SandsM.S., and DavidsonB.L. (2006). Gene therapy for lysosomal storage diseases. Mol. Ther., 13, 839–849.
47.
SavasP.S., HemsleyK.M., and HopwoodJ.J. (2004). Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol. Genet. Metab., 82, 273–285.
48.
SinhaS., SatishchandraP., SantoshV., et al. (2004). Neuronal ceroid lipofuscinosis: a clinicopathological study. Seizure, 13, 235–240.
49.
SondhiD., PetersonD.A., GiannarisE.L., et al. (2005). AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther., 12, 1618–1632.
50.
SondhiD., HackettN.R., PetersonD.A., et al. (2007). Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther., 15, 481–491.
51.
SondhiD., PetersonD.A., EdelsteinA.M., et al. (2008). Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol., 213, 18–27.
52.
SondhiD., HackettN.R., ScottE., et al. (2011). Correction of the lysosomal storage defect in mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal injection of AAV serotype rh.10 vector expressing the human CLN3 gene. Mol. Ther., 19[Supplement 1], S78.
53.
StaropoliJ.F., HaliwL., BiswasS., et al. (2012). Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One, 7, e38310.
54.
StefanisL., LarsenK.E., RideoutH.J., et al. (2001). Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci., 21, 9549–9560.
55.
The International Batten Disease Consortium. (1995). Isolation of a novel gene underlying Batten disease, CLN3. Cell, 82, 949–957.
56.
TomaninR., ZanettiA., ZaccariottoE., et al. (2012). Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr., 101, 692–701.
57.
TyynelaJ., CooperJ.D., KhanM.N., et al. (2004). Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol., 14, 349–357.
58.
WaddingtonS.N., KenneaN.L., BuckleyS.M., et al. (2004). Fetal and neonatal gene therapy: benefits and pitfalls. Gene Ther., 11Suppl. 1, S92–S97.
59.
WeimerJ.M., CusterA.W., BenedictJ.W., et al. (2006). Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis., 22, 284–293.
60.
WeimerJ.M., YokotaY., StancoA., et al. (2009). MARCKS modulates radial progenitor placement, proliferation and organization in the developing cerebral cortex. Development, 136, 2965–2975.
61.
WestM.J., SlomiankaL., and GundersenH.J. (1991). Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec., 231, 482–497.
62.
WorgallS., SondhiD., HackettN.R., et al. (2008). Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19, 463–474.
63.
YuW.H., CuervoA.M., KumarA., et al. (2005). Macroautophagy—a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol., 171, 87–98.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
